I n cardiac cells, depolarization of the external membrane and its infoldings, the T-tubules, opens voltage-sensitive Ca 2ϩ channels/dihydropyridine receptors (DHPRs), allowing a small influx of extracellular Ca 2ϩ (the inward Ca 2ϩ current, I Ca ). In mature cardiomyocytes, I Ca is insufficient to elevate myoplasmic [Ca 2ϩ ] to fully contracting levels; however, I Ca triggers the opening of Ca 2ϩ release channels/ ryanodine receptors (RyRs), which produce a rapid and massive release of Ca 2ϩ from the sarcoplasmic reticulum (SR). This amplification process, termed Ca 2ϩ -induced Ca 2ϩ release (CICR), 1 may be graded by endogenous effectors, hormones, and neurotransmitters to regulate the intensity and duration of ventricular contractions. 2 RyRs are homotetramers of more than 2 megadaltons endowed with more than a fair share of structural elements to produce a bona fide ion channel. They contain a highconductance Ca 2ϩ -selective pore, Ca 2ϩ activation and inactivation sites, several phosphorylation sites, and multiple binding sites for a myriad of endogenous regulators that include ATP, Mg 2ϩ , and calmodulin. 3, 4 Still, as if this huge structural assembly were not sufficiently complex, RyRs are also capable of protein-protein interactions that allow them to bind, in some cases steadily and in other cases in a time-and Ca 2ϩ -dependent manner, to small and independently regulated accessory proteins. 5 Therefore, although the RyR homotetramer with its intrinsic regulatory domains seems to be the central processor of effector signals, its association with cytosolic (FKBP12, sorcin, and calmodulin) and lumenal (calsequestrin, junctin, and triadin) proteins seems to add another layer of versatility (and complexity) to modulation of CICR in the heart. But how extensive is the level of involvement of these accessory proteins in CICR? Are they indispensable components of Ca 2ϩ release during excitationcontraction coupling? If not, do they play a role in other processes of the cell?
Probably for no other accessory protein of RyRs are these questions more pressing than for the immunophilin FKBP12 (FK506-binding protein 12 kDa). Originally identified in T cells as the cytosolic receptor for immunosuppressant drugs, 6 FKBP12 is a cis-trans peptidyl-prolyl isomerase that may bind to RyRs with a stoichiometry of 1(RyR protomer):1(FKBP12) or 4 FKBP12s per single functional channel. The RyR-FKBP12 complex is so stable that proteolytic fragments of purified RyR often appear to be contaminated with fragments of FKBP12, 7 and the immunophilin may be used in affinity columns to purify RyRs. 8 Furthermore, inositol trisphosphate receptors (IP 3 Rs), another major type of intracellular Ca 2ϩ release channels, also bind FKBP12 with high affinity. 9 Because IP 3 Rs play no major role in excitation-contraction coupling of striated muscle, this would suggest that FKBP12 might also be involved in interfacing Ca 2ϩ -signal amplification pathways unrelated to CICR. Despite the ubiquitous presence of FKBP12 in a variety of cells and its demonstrated association to RyRs, its role as a regulator of CICR remains controversial. Although it is clear that the immunosuppressant FK506 or rapamycin removes FKBP12 from skeletal RyRs (RyR1) or FKBP12.6 (a protein isoform) from cardiac RyRs (RyR2), 10, 11 there is disagreement regarding the functional consequences of such removal. Several studies have found that FKBP12.6-devoid RyRs reconstituted in lipid bilayers exhibit long-lived subconductance states with high frequency and tend to dwell in the open state for longer periods than control RyRs. 12, 13 Both effects led to the proposal that the immunophilin serves to stabilize RyRs in the closed conformational state. 11 However, other studies 14, 15 have found that removal of FKBP12.6 has no significant effect on the Ca 2ϩ dependency or gating behavior of cardiac RyRs. Different interpretations have also resulted from the effect of immunosuppressants on intact ventricular myocytes. Xiao et al 13 found that FK506 increased the frequency and duration of Ca 2ϩ sparks, consistent with the role for FKBP12 postulated above, but other studies failed to detect alterations in the Ca 2ϩ transient 16 19 Instead, major alterations were detected in the heart of the transgenic mice, which had RyRs with high incidence of long-lived subconductance states. The latter results were also puzzling, because cardiac RyRs presumably associate with FKBP12.6 only, 14, 15 14, 15 binding of FKBP12 to cardiac RyRs in intact cells has not been ruled out. Second, some experiments involved the use of rapamycin, which blunts the effects of FKBP12 and FKBP12.6 with equal effectiveness. 6 If different levels of FKBP12 had been observed, a potential indirect effect of FKBP12 on the measured parameters would have complicated the interpretation of the results. A major downside of the approach is that in an effort to reveal the function of a given protein, cells are forced to express large quantities of the same that might, in fact, generate an artificial function. Realistically, the experiments of Prestle et al 23 reveal what FKBP12.6 is capable of doing more than what it actually does in a normal cell environment. Even then, interesting conclusions could be extracted.
The first striking observation of Prestle et al 23 is that the expression of FKBP12.6 assessed at the protein (Western blot) and RNA (reverse transcriptase-polymerase chain reaction) levels in control, noninfected cells is significantly lower than that of FKBP12 and perhaps insufficient to bind to RyRs with the proposed ratio of 4(FKBP12.6):1(RyR tetramer). Under these conditions, it might be possible that FKBP12 compensates for the low levels of FKBP12.6 and binds to cardiac RyRs despite the demonstrated adversity of the reaction. 14, 15 However, a functional assay of immunophilin effect on RyRs used in the study showed that rapamycin, which effectively blocks FKBP12 and FKBP12.6, only marginally decreased the RyR-mediated Ca 2ϩ efflux rate in control cells but significantly increased the same in FKBP12.6-overexpressing cells. Thus, it seems that cardiac RyRs are indeed selective targets of FKBP12.6 but that their low quantity in cardiac cells draws out a barely detectable effect, at least in this aspect of RyR function. Again, with risk of oversimplification, these results tend to suggest that major roles for the immunophilins in cardiomyocytes reside in cellular aspects other than CICR.
There are results, however, in the study by Prestle et al 23 that suggest that overexpression of FKBP12.6 does affect CICR if we assume that all effects of the immunophilin are attributable to regulation of RyR function. For example, the size of cell contractions was increased in FKBP12.6-overexpressing cells, suggesting that SR Ca 2ϩ release was increased. Interestingly, the kinetics of cell contractions were not increased. Time to peak and time to 50% relengthening of cell shortenings were actually slowed or unmodified by FKBP12.6. Again, circumscribing the effects of FKBP12.6 to RyRs and barring its potential effects on other proteins of excitation-contraction coupling, the bigger but slower contractions of FKBP12.6-overexpressing cells are in agreement with the notion that a slow component of, but not the initial, RyR-mediated Ca 2ϩ release efflux was increased by the immunophilin. However, even in such a case, the cellular effects of FKBP12.6 cannot be reconciled with those obtained with single RyR channels without invoking the involvement of additional regulatory mechanisms. In the above scheme, FKBP12.6 could be presented as a promoter of RyR openings that sustains longer than normal SR Ca 2ϩ efflux, whereas in lipid bilayer experiments, FKBP12.6 is seen as a promoter of RyR closings, because FKBP12. 23 detected only modest effects in experiments that blocked the native population of immunophilins in cardiac cells. It was not until cardiac cells were forced to overexpress FKBP12.6 that the effects of the immunophilin became more apparent. Thus, the majority of their results may be interpreted as a gain of function for RyRs, not the unveiling of a normal RyR function. Timerman et al 14 estimated that Ϸ17% of the total FKBP12.6-binding sites of dog cardiac SR were unoccupied. If that were the case in rabbit cardiomyocytes (the cells used by Prestle et al 23 ) , there would seem to be few RyRs for new FKBP12.6 molecules to interact with. However, initial control experiments by Prestle et al 23 showed that FKBP12.6 was hardly expressed in rabbit cardiomyocytes, and overexpression would therefore seem justified to reveal a function. The challenge ahead is to determine the normal levels of FKBP12.6 across species and during different stages of cell development to determine their contribution to CICR and other aspects of cell function.
